Fc engineering / effector function
Tweaking the antibody's tail to make it recruit immune cells more strongly, or not at all.
Afucosylation and Fc mutations enhance ADCC; Fc-silencing (IgG4, LALA mutations) prevents unwanted immune activation in checkpoint inhibitors and T-cell engagers. Half-life extension via FcRn-binding mutations.
Pages like this
not linked directly; found by shared links- TermADCC (antibody-dependent cellular cytotoxicity)
Shares Mogamulizumab, Margetuximab, NK cell, University Hospital Southampton / Centre for Cancer Immunology.
- TargetCCR4
Shares Mogamulizumab, Monoclonal antibodies.
- ProductMagrolimab
Shares Bispecific antibodies that engage macrophages instead of T cells, Myeloid suppression: TAMs, MDSCs & don't-eat-me signals, Monoclonal antibodies.
- TechnologyCAR-NK & CAR-macrophage
Shares NK cell, Bispecific antibodies that engage macrophages instead of T cells, Myeloid suppression: TAMs, MDSCs & don't-eat-me signals, NK-cell recognition: missing self & stress ligands.
- TargetCSF1R
Shares Complement in cancer, Myeloid suppression: TAMs, MDSCs & don't-eat-me signals, Monoclonal antibodies.
- TermMonoclonal
Shares Antibody, Monoclonal antibodies.
- TermCell membrane
Shares Antibody, Monoclonal antibodies.
- TermMyeloid-derived suppressor cells (MDSCs)
Shares Complement in cancer, Myeloid suppression: TAMs, MDSCs & don't-eat-me signals.